Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230].
作者信息
de Zafra Christina L Zuch, Sasseville Vito G, Matsumoto Steven, Freichel Christian, Milton Mark, MacLachlan Timothy K, Farman Cindy, Raymond Iona, Gupta Swati, Newton Ronald, Atzpodien Elke-Astrid, Thackaberry Evan A
机构信息
Safety Assessment, Genentech, Inc., South San Francisco, CA, United States.
Preclinical Safety, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
出版信息
Regul Toxicol Pharmacol. 2017 Aug;88:364. doi: 10.1016/j.yrtph.2017.04.006. Epub 2017 Apr 18.
PMID:28431771
Abstract
摘要
Zotero 插件